SCHEMBL22493447

SCHEMBL22493447

Cc1ncc(Cl)cc1CCNC(C)(C)C

nearest known ligand 0.36

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ HRH4 Q9H3N8 2/20 0.33
▸ HRH3 Q9Y5N1 2/20 0.33
▸ MEN1 O00255 3/20 0.32
▸ KMT2A Q03164 3/20 0.32
▸ ALDH1A1 P00352 2/20 0.32
▸ KDM4E B2RXH2 2/20 0.32
▸ LMNA P02545 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ PKM P14618 1/20 0.32
▸ CYP1A2 P05177 2/20 0.31
▸ CYP2C8 P10632 2/20 0.31
▸ CYP2D6 P10635 2/20 0.31
▸ CYP2C19 P33261 2/20 0.31
▸ CYP2C9 P11712 1/20 0.31
▸ CRHR1 P34998 1/20 0.31
▸ KCNH2 Q12809 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22493446 0.81 HRH4 (0.33) HRH4HRH3
SCHEMBL26859257 0.71 LMNA (0.35) HRH4HRH3ALDH1A1KDM4ELMNA
SCHEMBL13180337 0.71 NOS3 (0.39) MEN1KMT2ALMNACRHR1
SCHEMBL29722048 0.70 HRH4 (0.37) HRH4HRH3MEN1KMT2AALDH1A1
SCHEMBL22493402 0.70 P2RX7 (0.37) CYP2C9
SCHEMBL31277002 0.70 CRHR1 (0.33) MEN1KMT2ALMNACRHR1
SCHEMBL1239864 0.70 KDM4E (0.46) MEN1KMT2AALDH1A1KDM4ELMNA
SCHEMBL1239058 0.70 KDM4E (0.39) HRH4MEN1KMT2AKDM4ELMNA
SCHEMBL32689803 0.69 PLAU (0.58) LMNA
SCHEMBL22480868 0.68 ADRB2 (0.50) MEN1KMT2AKDM4ELMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024137506-A1 COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS CURASEN THERAPEUTICS, INC. (US) 2024-06-27 — — WO disclosed
WO-2023225021-A1 COMPOSITIONS AND METHODS FOR TREATING PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) CURASEN THERAPEUTICS, INC. (US) 2023-11-23 — — WO disclosed
WO-2020198466-A9 BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME CURASEN THERAPEUTICS, INC. (US) 2020-12-30 — — WO disclosed
WO-2020198466-A1 BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME CURASEN THERAPEUTICS, INC. (US) 2020-10-01 — — WO disclosed
Send feedback